COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1-2a, Single Dose Study Investigating NTLA-5001 in Subjects with Acute Myeloid Leukemia

Protocol No
INTELLIA-NTLA-5001-CL-001-AML
Principal Investigator
Sameem Abedin
Phase
I/II
Summary
The purpose of this study is to learn about the effects of a new investigational medicine, NTLA 5001.
Description
Single Dose Study Investigating NTLA-5001 in Subjects with AML
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL